The introduction of CAR T-cell therapies and bispecific antibodies has transformed treatment of multiple myeloma (MM). However, these agents also pose unique safety challenges that may be unfamiliar to busy ED physicians. As more patients receive these immunotherapies, they may increasingly present to the ED for treatment of complications including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

ED clinicians must prepare now for this influx by increasing their ability to diagnose and mitigate immunotherapy associated adverse events. Join Dr. Richter as he discusses the skills needed to manage these complex scenarios and support improved outcomes in MM patients treated with novel immunotherapies.